Details for New Drug Application (NDA): 215331
✉ Email this page to a colleague
NDA 215331 describes BORTEZOMIB, which is a drug marketed by Accord Hlthcare, Apotex, Baxter Hlthcare Corp, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Hospira, Jiangsu Hansoh Pharm, Meitheal, MSN, Mylan Labs Ltd, Pharmascience Inc, Qilu Pharm Hainan, Sandoz, Scinopharm Taiwan, Teva Pharms Usa, Waverley Pharma Inc, Zydus Pharms, and Maia Pharms Inc, and is included in twenty-three NDAs. It is available from nineteen suppliers. There are three patents protecting this drug. Additional details are available on the BORTEZOMIB profile page.
The generic ingredient in BORTEZOMIB is bortezomib. There are twenty drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the bortezomib profile page.
The generic ingredient in BORTEZOMIB is bortezomib. There are twenty drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the bortezomib profile page.
Summary for 215331
| Tradename: | BORTEZOMIB |
| Applicant: | Maia Pharms Inc |
| Ingredient: | bortezomib |
| Patents: | 2 |
| Formulation / Manufacturing: | see details |
Pharmacology for NDA: 215331
| Mechanism of Action | Proteasome Inhibitors |
Medical Subject Heading (MeSH) Categories for 215331
Suppliers and Packaging for NDA: 215331
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| BORTEZOMIB | bortezomib | SOLUTION;INTRAVENOUS | 215331 | NDA | MAIA Pharmaceuticals, Inc. | 70511-161 | 70511-161-05 | 1 INJECTION in 1 VIAL, SINGLE-DOSE (70511-161-05) |
| BORTEZOMIB | bortezomib | SOLUTION;INTRAVENOUS | 215331 | NDA | MAIA Pharmaceuticals, Inc. | 70511-162 | 70511-162-02 | 1 INJECTION in 1 VIAL, SINGLE-DOSE (70511-162-02) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS | Strength | 3.5MG/3.5ML (1MG/ML) | ||||
| Approval Date: | Jul 27, 2022 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Try a Trial | Patent Expiration: | Sep 23, 2042 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA | ||||||||
| Patent: | ⤷ Try a Trial | Patent Expiration: | Sep 23, 2042 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA | ||||||||
| Patent: | ⤷ Try a Trial | Patent Expiration: | Sep 23, 2042 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA | ||||||||
Complete Access Available with Subscription
